Bath News

Brand new sexual health test set to revolutionise the industry

Share Article

Written by: Tim MacFarlan | Posted 16 February 2016 16:48

Brand new sexual health test set to revolutionise the industry

A company run by a former University of Bath lecturer has secured permission to market a unique 30 minute Chlamydia test.

Atlas Genetics Ltd, which develops Point-Of-Care (POC) molecular diagnostics devices, has received approval to sell the Chlamydia trachomatis (CT) test across the European Union on the company’s io platform. 

It will be the first molecular POC test for a Sexually Transmitted Infection (STI) to enter the market, with the aim of testing and treatment of patients within a single visit to an STI clinic.

The io platform helps deliver this result immediately to the patient which has the potential to improve patient outcomes, decrease onward transmission and reduce healthcare costs.

John Clarkson, CEO of Atlas Genetics, is a former lecturer in University of Bath’s Department of Biology and Biochemistry who recruited a number of researchers from his old department to help with the development of the Atlas io platform.

He said: “This is a major milestone for Atlas Genetics and marks the beginning of the next phase of growth for Atlas as we move to commercialise our first product and expand the io infectious disease menu of tests. STIs are on the rise and the faster a diagnosis can be made, the faster treatment can be given, not only benefiting the patient but also saving time and money. We believe that our io platform will play a key role in the future of STI diagnosis.”

The Chlamydia test is the first in a series to be launched on the io platform, including tests for Gonorrhoea, Trichomonas vaginalis and other STIs for both the European and US markets. While Atlas is initially focusing on sexual health, the io platform can be applied in a wide range of infectious disease and oncology diagnostic test areas. 

Share Article